Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease - eBioMedicine

Keep calm: the intestinal barrier at the interface of peace and war

Frontiers Intestinal Barrier Function and Immune Homeostasis Are Missing Links in Obesity and Type 2 Diabetes Development

Evaluation of Intestinal Epithelial Barrier Function in Inflammatory Bowel Diseases Using Murine Intestinal Organoids. - Abstract - Europe PMC

Full article: Beta-carotene regulates the biological activity of EGF in IEC6 cells by alleviating the inflammatory process

uPAR Antibody AF807 from R&D Systems, a Bio-Techne Brand

TRIM40 is a pathogenic driver of inflammatory bowel disease subverting intestinal barrier integrity. - Abstract - Europe PMC

Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease. - Abstract - Europe PMC

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer, Journal of Translational Medicine

Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy, Journal of Nanobiotechnology

Frontiers Role of glycolysis in inflammatory bowel disease and its associated colorectal cancer

Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics

Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine, Journal of Translational Medicine

PDF) Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer

PDF) Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer

Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease - ScienceDirect